Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
71.9M
-
Number of holders
-
8
-
Total 13F shares, excl. options
-
8.98M
-
Shares change
-
-1.31M
-
Total reported value, excl. options
-
$225M
-
Value change
-
-$844K
-
Number of buys
-
3
-
Number of sells
-
-1
-
Price
-
$6.47
Significant Holders of SINOVAC BIOTECH LTD. - Common Shares (SVA) as of Q3 2025
9 filings reported holding SVA - SINOVAC BIOTECH LTD. - Common Shares as of Q3 2025.
SINOVAC BIOTECH LTD. - Common Shares (SVA) has 8 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.98M shares
of 71.9M outstanding shares and own 12.5% of the company stock.
Largest 9 shareholders include Vivo Capital, LLC (5.9M shares), ORBIMED ADVISORS LLC (2.72M shares), Neumann Advisory Hong Kong Ltd (316K shares), WELLS FARGO & COMPANY/MN (16.9K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (16.4K shares), MORGAN STANLEY (9.14K shares), UBS Group AG (2.22K shares), Horizon Investments, LLC (52 shares), and RENAISSANCE TECHNOLOGIES LLC (0 shares).
This table shows the top 8 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.